Evidence map›Paper›PMID 33118518›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2020

[Zoledronate regulates osteoclast differentiation and bone resorption in high glucose through p38 MAPK pathway].

Yifan Lin, Yingying Gu, Guifu Zuo, Shunyi Jia, Yongqiang Liang, Mengchun Qi, Wei Dong

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yifan LinSchool of Stomatology, North China University of Science and Technology, Tangshan 063210, China.
Yingying GuSchool of Stomatology, North China University of Science and Technology, Tangshan 063210, China.
Guifu ZuoSchool of Materials Science and Engineering, North China University of Science and Technology, Tangshan 063210, China.
Shunyi JiaSchool of Stomatology, North China University of Science and Technology, Tangshan 063210, China.
Yongqiang LiangSchool of Stomatology, North China University of Science and Technology, Tangshan 063210, China.
Mengchun QiSchool of Stomatology, North China University of Science and Technology, Tangshan 063210, China.
Wei DongSchool of Stomatology, North China University of Science and Technology, Tangshan 063210, China.
North China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effect of zoledronate (ZOL) on osteoclast differentiation and bone resorption under high glucose, and the regulation mechanism of p38 mitogen activated kinase (p38 MAPK) signaling pathway in this process.

methodsRAW264.7 cells were divided into four groups: low group, high group, low+ZOL group and high+ZOL group after induced into osteoclasts. Cell proliferation activity was determined by MTT assay. The migration of RAW264.7 cells were examined Optical microscopy. Immunofluorescence microscopy was used to observe the cytoskeleton and sealing zones of osteoclasts. After adding group 5: high + ZOL + SB203580 group, trap staining was used to identify the number of positive osteoclasts in each group. The number and area of resorption lacunae were observed by SEM. The mRNA and protein expression of osteoclast related factors were detected by real-time PCR and Western blotting.

resultsThe cells in the 5 groups showed similar proliferative activity. High glucose promoted the migration of RAW264.7 cells (

conclusionsHigh glucose inhibits osteoclast differentiation and bone resorption. ZOL inhibits osteoclast differentiation and bone resorption in high-glucose conditions by regulating p38 MAPK pathway, which can be a new pathway for ZOL to regulate diabetic osteoporosis.

Indexed as

Bone ResorptionOsteoclastsAnimalsCell DifferentiationGlucoseMAP Kinase Signaling SystemMiceNFATC Transcription Factorsp38 Mitogen-Activated Protein KinasesRANK LigandZoledronic AcidGlucoseNFATC Transcription Factorsp38 Mitogen-Activated Protein KinasesRANK LigandZoledronic Acidhigh glucoseosteoclastp38 mitogen-activated kinasezoledronate

Identifiers

PMID33118518
PMCPMC7606243
OpenAlexW3097238103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.